This episode explores diabetes pharmacology as the art of precision under pressure. Glucose regulation is not a single pathway but a constantly negotiated truce between intake, storage, release, and utilisation. We examine insulin biology alongside non-insulin glucose-lowering therapies to show why modern diabetes care is less about domination of numbers and more about alignment with physiology. The episode frames hypoglycaemia as the central danger, variability as the true enemy, and personalised therapy as the clinical goal.

Key takeaways to anchor learning:

* Dual failure patterns: insulin deficiency versus insulin resistance.

* Insulin as a signal, not just a drug: timing, peaks, and tissue specificity.

* Non-insulin agents: metformin, incretins, SGLT2 inhibitors, and why they matter.

* Hypoglycaemia risk: the price of overtreatment and how to minimise it.

* Therapeutic strategy: matching drug choice to disease stage and patient context.

This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit drmanaankarray.substack.com/subscribe